Premium
Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrenty wheezy infants
Author(s) -
Moeller Alexander,
Franklin Peter,
Hall Graham L.,
Turner Steve,
Straub Daniel,
Wildhaber Johannes H.,
Stick Stephen M.
Publication year - 2004
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.20055
Subject(s) - medicine , wheeze , exhaled nitric oxide , placebo , atopy , asthma , anesthesia , fluticasone , lung function , corticosteroid , spirometry , pediatrics , lung , alternative medicine , pathology
We examined the effect of inhaled fluticasone diproprionate (FDP) on symptoms, lung function (FEV 0.5 ), and exhaled nitric oxide (Fe NO ) in infants with recurrent wheeze and raised Fe NO . Thirty‐one infants aged 6–19 months (mean, 12.7 months; 12 girls) completed the study. All infants had a history of recurrent wheeze and a parental history of atopy. All children had raised Fe NO , as determined by an offline tidal breathing technique prior to randomization. Lung function and Fe NO were assessed before and after 4 weeks of treatment with FDP or placebo. The parents recorded daily symptoms during the treatment period. Sixteen infants received FDP and 15 the placebo for 4 weeks. At completion of the study, infants treated with FDP had a significant reduction in Fe NO (35.0 ppb to 16.5 ppb) compared to those that received placebo (35.2 ppb to 30.2 ppb) ( P = 0.05). Small increases in FEV 0.5 were observed in both groups, but these changes were not different between groups ( P = 0.8). Symptom scores were not significantly different in either group following the intervention. We showed that a moderate dose of inhaled FDP reduces levels of Fe NO , a potential marker of airway inflammation, even in the absence of significant changes in lung function and symptoms. © 2004 Wiley‐Liss, Inc.